Alcon Reports Results for Dry-Eye-Treatment Trials
By Denny Jacob
Alcon reported topline results from two trials evaluating AR-15512, a candidate treatment for dry-eye disease.
The eye-care company said the primary endpoint achieved statistical significance in both trials. Additional data derived from secondary endpoints demonstrated the rapid onset and sustained tear production, said Alcon.
AR-15512 was well tolerated and no serious ocular adverse events were reported.
Alcon expects to file a new drug application for AR-15512 with the U.S. Food and Drug Administration in mid-2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 09, 2024 17:05 ET (22:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters